BRISTOL MYERS SQUIBB CO•Financial Summary•AI-Powered Insights

BRISTOL MYERS SQUIBB CO 2024 Q2
Earnings Overview & AI Insights

Detailed performance report for BRISTOL MYERS SQUIBB CO covering Q2 2024. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.

BRISTOL MYERS SQUIBB CO (2024 Q2)

Earnings Performance

No Performance Data

Christopher S. Boerner is Chairman and Chief Executive Officer of BMS. He says he's focused on reshaping BMS to achieve sustained top-tier growth and maximize long-term value. The company's second-quarter results reflect continued progress against our strategy to position BMS for sustainable growth. The company is on track to achieve $1.5 billion in cost savings we announced in Q1. We are strategically allocating capital for long-term growth and returns. We're executing on our cost reduction efforts and are on track to achieve the $1,000 billion in savings announced. We remain focused on ensuring we are investing behind our growth portfolio and critical assets. On Slide 8, I want to highlight a few important pipeline milestones across our therapeutic therapeuticareas this year. In hematology and oncology, we're extending our IO-franchise with nivolumab subcu and lung data. We expect to see data this year for CD19NEX-T in CD19-T. We're also expanding KarXT to additional indications with data expected in schizophrenia in 2025. Milvexian, which has the potential to deliver significant benefits for patients, form a large commercial opportunity for the company. We are confident in our ability to further strengthen our growth profile. David will discuss these updates in more detail shortly. Second-quarter sales performance reflect continued momentum for several important growth brands. Opdivo remains an important product than our immunology-oncology business. Eliquis remains the market leader, anticoagulant worldwide with global sales of more than $3 billion. Camzyos' second-quarter sales more than tripled compared to the prior year. Sales of Reblozyl in the quarter grew 82% and with growth in both U.S. and international markets. In cell therapy, we saw quarterly-over-quarter sales growth with Abecma driven largely by ex-U.S., in cell therapy. During the second quarter, we reduced our total global debt position by $3.1 billion, including roughly $2.7 billion in commercial paper and $400 million of long-term debt. Overall, earnings per share was $2,07 in the quarter, and we closed the quarter on June 30th, with $7 billion cash, cash and marketable debt securities on hand. On Q2 performance, focused execution across the                business generated top-line growth and driving operational excellence. Our guidance for the full-year is low single-digit growth, which we now expect to come in at the upper end end of the.                range.growth in the second half in relation to phasing of product sales in the back half of the year, keep in mind the typical product seasonality we expect to see in the third quarter. We now expect full-year sales to be at the higher end of our $4.5 billion to $5 billion sales range. We are committed to investing in high-growth areas where we have competitive advantages to meet the needs of our patients.

Earnings Call Transcript

Access the official earnings call transcript for BRISTOL-MYERS-SQUIBB-CO 2024 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.